Non-Hodgkin Lymphoma | Specialty

Axicabtagene Ciloleucel Approved in Japan for Relapsed/Refractory LBCL

January 22nd 2021

January 22, 2021 — The Japan Ministry of Health, Labour and Welfare has approved the CAR T-cell therapy axicabtagene ciloleucel for use in the treatment of adult patients with certain relapsed/refractory large B-cell lymphomas.

Parsaclisib Yields Encouraging Clinical Activity in Marginal Zone Lymphoma

January 21st 2021

Tycel Phillips, MD, highlighted the key findings of the phase 2 CITADEL-204 trial.

1-Year DFS Rates Similar Between Ibrutinib and Placebo Following Ibrutinib/Venetoclax in CLL

January 21st 2021

William G. Wierda, MD, PhD, discusses the latest CAPTIVATE findings in patients with chronic lymphocytic leukemia.

Remaining ECHELON-2 Questions Spark Novel Research Efforts in PTCL

January 19th 2021

Jakub Svoboda, MD, discusses the results of the ECHELON-2 trial and explained where clinical research is headed in peripheral T-cell lymphoma.

Frontline Treatment Options in Chronic Lymphocytic Leukemia

January 19th 2021

The experts comment on first-line treatment options in patients with chronic lymphocytic leukemia.

Guidelines for Chronic Lymphocytic Leukemia

January 19th 2021

Dr Brown and Dr Ghia discuss the European Society for Medical Oncology [ESMO] and International Workshop on Chronic Lymphocytic Leukemia [iwCLL] recommended guidelines in assessing and treating chronic lymphocytic leukemia.

Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study

January 18th 2021

Dr. Shah on the Safety of a Novel Dual-Targeted CAR T-Cell Therapy in Non-Hodgkin Lymphoma

January 14th 2021

Nirav Shah, MD, MCW, discusses the safety profile of an anti-CD20/anti-CD19 CAR T-cell therapy under investigation in the treatment of patients with non-Hodgkin lymphoma.

FDA Approves Crizotinib for Pediatric and Young Adult ALK+ Anaplastic Large Cell Lymphoma

January 14th 2021

January 14, 2021 - The FDA has approved crizotinib for the treatment of pediatric patients 1 year of age and older and young adults with ALK-positive relapsed or refractory, systemic anaplastic large cell lymphoma.

CLL Paradigm Prepares to Expand With Novel Therapies as Chemo Is Phased Out

January 13th 2021

James Gerson, MD, discusses how he navigates treatment selection for patients with CLL and exciting developments in the pipeline.

Ibrutinib/Rituximab Approved in Canada for CLL

January 13th 2021

January 13, 2021 - Health Canada has approved the combination of ibrutinib and rituximab for use in patients with treatment-naïve chronic lymphocytic leukemia.

COVID-19 Pandemic Restructures Care in CLL

January 12th 2021

As the coronavirus disease 2019 pandemic continues to pose challenges, health care providers struggle with decisions on how to balance the risk of severe acute respiratory syndrome coronavirus 2 transmission with the need to treat patients’ underlying conditions.

Dr. Shah on the Rationale for Tandem Receptor CAR T-Cell Therapy in Non-Hodgkin Lymphoma

January 11th 2021

Nirav N. Shah, MD, discusses the rationale to evaluate tandem receptor CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Lee on the Tolerability of Ibrutinib/Cirmtuzumab in MCL and CLL

January 8th 2021

Hun Ju Lee, MD, discusses the tolerability of ibrutinib plus cirmtuzumab in mantle cell lymphoma and chronic lymphocytic lymphoma.

Frontline CLL Treatment: Addressing Unmet Needs

January 8th 2021

Allogeneic Transplantation for CLL

January 8th 2021

Relapsed/Refractory CLL: Repeat Molecular Testing

January 8th 2021

Therapeutic Sequencing in Relapsed/Refractory CLL

January 8th 2021

CLL Patient Management During COVID-19 and Telehealth

January 8th 2021

CLL Treatment Approaches During COVID-19

January 8th 2021